LIVE WEBINAR: Wednesday, June 14, 2023, 5:00 PM – 6:00 PM Eastern Time

What I Tell My Patients: Faculty Physicians and Nurses Discuss Patient Education About New Treatments and Clinical Trials — Colorectal and Gastroesophageal Cancers

Part 2 of a 3-Part Complimentary NCPD Webinar Series in Partnership with the 2023 ONS Congress


Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Wednesday, June 14th for this NCPD-accredited webinar
5:00 PM – 6:00 PM ET

Kristen K Ciombor, MD, MSCI
Associate Professor of Medicine
Division of Hematology/Oncology
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Amanda K Wagner, APRN-CNP, AOCNP
GI Malignancies
The James Cancer Hospital
The Ohio State University
Columbus, Ohio

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by educational grants from Astellas and Seagen Inc.

Wednesday, June 14, 2023
5:00 PM – 6:00 PM Eastern Time
Live NCPD-accredited webinar

A detailed agenda will be made available in the coming weeks.

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of colorectal and gastroesophageal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Educate patients with metastatic colorectal cancer (mCRC) regarding the impact of biomarker profile, tumor location, prior systemic therapy, symptomatology and personal goals of treatment on the selection and sequencing of therapy.
  • Appreciate published research data documenting the efficacy of combined BRAF/EGFR inhibition for patients with relapsed/refractory mCRC and a BRAF V600E mutation, and understand how this approach is being optimally incorporated into the current care of appropriate patients.
  • Evaluate available data with and the FDA approvals of various immune checkpoint inhibitor based approaches for microsatellite instability-high or mismatch repair-deficient mCRC, and identify individuals for treatment with this form of therapy.
  • Recognize available data with anti-HER2 therapy in patients with HER2-positive mCRC and consider the current and future role of various investigational approaches.
  • Assess the relevance of HER2 status, PD-L1 combined positive score, clinical factors and patient preferences in order to develop strategies to counsel individuals with locally advanced or metastatic gastric/gastroesophageal junction cancer regarding personalized treatment recommendations.
  • Describe the published research data with the use of immune checkpoint inhibitors alone or in combination with chemotherapy in the management of gastric/gastroesophageal junction cancer, and optimally integrate these strategies into nonprotocol treatment algorithms.
  • Recall the biologic rationale for and available data with the use of HER2 targeted therapy for patients with HER2 overexpressing gastric/gastroesophageal junction cancer and discern the current and potential future clinical applicability of available treatment strategies.
  • Recognize common and rare side effects associated with approved and investigational agents used in the care of patients with colorectal and gastroesophageal cancers, and apply this information to develop appropriate and effective supportive management plans.
  • Recall available and emerging data with investigational agents and strategies currently in clinical testing for colorectal and gastroesophageal cancers, and, where applicable, refer eligible patients for trial participation.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

NCPD Designation Statements
This educational activity for 1 contact hour is provided by RTP.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Astellas and Seagen Inc.